RVMD241220C38000
- 0.00
- 0.000.00%
Revolution Medicines Newsroom
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight
J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $63
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $80
Bank of America Securities Keeps Their Buy Rating on Revolution Medicines (RVMD)
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $63 to $72
Revolution Medicines Is Maintained at Overweight by Piper Sandler
Revolution Medicines Analyst Ratings
Optimistic Growth Prospects for Revolution Medicines With Promising Data Updates and Increased Price Target
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $64 to $72
Revolution Medicines Q3 Loss Narrows; Reaffirms Full-Year Guidance
Analysts' Top Healthcare Picks: CVS Health (CVS), Revolution Medicines (RVMD)
Express News | Revolution Medicines Inc : JP Morgan Raises Target Price to $63 From $54
Revolution Medicines: Strong Buy Rating Backed by Financial Stability and Promising Cancer Treatment Advances
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript Summary
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
Express News | Revolution Medicines: Projects Current Cash, Cash Equivalents and Marketable Securities Can Fund Planned Operations Into 2027
10-Q: Q3 2024 Earnings Report
Revolution Medicines GAAP EPS of -$0.94 Misses by $0.04